New Biotech Funding Models: Is the Tech Revolution Coming?

November 12, 2019 8:00 AM - 10:00 AM

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139

Add to Calendar 11/12/2019 8:00:00 AM 11/12/2019 10:00:00 AM New Biotech Funding Models: Is the Tech Revolution Coming?

Early-stage financing and company creation models have evolved significantly over the last two decades from heavily-funded, brick & mortar, do or die entities to angel-enabled, virtual and minimalistic proof of concept start-ups with hand-selected management and externally-enabled resources and ecosystems. Indeed, the Funding Model for emerging biotech companies appears to borrow from the tech company funding models from two decades prior, including incubators and accelerators, angel investors, shared laboratory and clinical facilities, “venture engineering” and shared resource programs. At this MassBio program, under the auspices of Entrepreneurs University, we will explore the current funding models in vogue today, the investor landscape, the impact of advancing science and technology, new types of partnerships, and the novel approaches early-stage companies are executing to advance to the next stage of existence – and funding round. Finally, our panel will provide their ideas on the future of venture funding and early-stage funding models in the biotech industry, and open the program to a lively discussion with the audience. Our moderator for this program is the inimitable, ever-effervescent John Hession. Please join us.

Sponsored by the MassBio Entrepreneurs University Working group.

MassBio, 300 Technology Square 8th Fl, Cambridge, MA 02139
Chief Business Officer, MassBio
John Hallinan joined MassBio in 2012 as the Chief Business Officer and oversees the MassBio Innovation Services programs. John’s fiscal experience in the life sciences and software industries reflect positions of increasing responsibility across a broad range of strategic and operational disciplines. His background encompasses venture financings, corporate development, technology licensing, and mergers and acquisitions. Prior to MassBio, John was the Chief Financial Officer at Cytel, a leader in the design and implementation of adaptive clinical trials, and he had been active with MassBio—serving on the Economic Development Advisory Group and as co-chair of the Finance Committee & Entrepreneur’s University. Before joining Cytel, John served as CFO at Signet Laboratories, a leading supplier of diagnostic assays to the pharmaceutical and biotech industries. Prior to Signet, John was interim CFO at Cambium Learning, a private equity-backed publishing company that completed two acquisitions during his tenure. John was the Chief Financial Officer of AnVil, Inc. a venture-funded silico drug discovery company, where he led the company’s healthcare market business development efforts. At CambridgeSoft Corporation, John rose to CFO of that leading pharma/bio applications and enterprise solutions supplier. As Animation Technologies’ CFO, he guided the company’s first and second rounds of venture funding. John currently sits on the Advisory Board of MTTC (the MA Technology Transfer Center) and Charité BIH Entrepreneurship Summit. John holds a BBA from St. Bonaventure University and is a certified public accountant. He lives with his wife Denise in Marlborough, MA.